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by combining several of these proteins were found to be associ-
ated with fewer reactions and were efﬁcacious. Acellular vaccines
soon replaced whole cell vaccines in many countries, but because
of reduced cost and proven efﬁcacy, whole cell vaccines are still
used inmost developing countries. Therehas been a recent increase
in reported pertussis cases observed in many countries using the
acellular vaccines, especially in young adolescents between 7 to 14
years of age. The reasons for this increase are complex and mul-
tifactorial and include greater intensity of surveillance, improved
method to diagnose pertussis, changes in the biologic charac-
teristics of the Bordetella pertussis organisms, and the types and
schedules of pertussis vaccines used for routine vaccination. Cur-
rent acellular vaccines have been shown to be efﬁcacious in the
short term, but in actual use are failing to be effective in controlling
pertussis in the long term. Recent data suggest that the acellu-
lar vaccines are associated with more rapid waning of immunity,
and that priming with whole cell pertussis vaccine is more effec-
tive than acellular vaccine in preventing disease. There is a clear
need to better understand the differences in the immune responses
induced by acellular and whole cell vaccines after both the pri-
mary and booster series. Nonhuman primate models are shedding
light on the differences in the prevention of disease and transmis-
sion with acellular and whole cell vaccines and on the differences
in immune responses to both vaccine types. Strategies to improve
the current acellular vaccines include; reintroduction of whole cell
vaccines into the vaccine series, the addition of new antigens to
the currently available acellular vaccines, the use of adjuvants to
enhance speciﬁc immune responses, and the utility of a new live
attenuated intranasal pertussis vaccine
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Recent estimates on the burden of DENV infection deter-
mined that there are 390 million dengue infections per year,
three times the current estimate by the WHO. Since vector
control programs have been largely unsuccessful in preventing
outbreaks, vaccination seems to be the most viable option for
prevention. The development of dengue vaccines has been ham-
pered by the theoretical risk of vaccine-related adverse events
such as immune enhancement, and the requirement to induce a
long-lasting protective immune response against all four dengue
serotypes simultaneously. Other challenges include the lack of an
adequate animal model of disease, absence of an immune corre-
late of protection, and only partially informative immunogenicity
assays. Currently, several kinds of dengue vaccines are in develop-
ment, but only one of these candidates (a chimeric dengue-yellow
fever live attenuated vaccine) has reached the stage of phase 3 clin-
ical trials. Live dengue vaccine candidates have been administered
to ten thousands of volunteers and were well-tolerated, with mini-
mal short-termsafetyeffects reported inPhase I andPhase II clinical
trials. Based on the natural history of dengue, a theoretical possi-
bility of an increased risk of severe dengue as a consequence of
vaccination has been hypothesized but not yet observed. Despite
good safety and immunogenicity proﬁles registered, issues such as
imbalanced immune responses between serotypes and lack of clin-
ical protective efﬁcacy in the ﬁrst results of Phase 3 trials have been
a major set-back in the development of an urgently needed dengue
vaccine.
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As of December 18, 360 cases of wild type 1 poliomyelitis
and 58 cases of paralysis caused by circulating vaccine-derived
polioviruses (cVDPV) were reported to WHO in 2013 compared
with 223 wild type and 70 cVDPV in calendar year 2012. No wild
type 3 cased occurred and all cVDPV cases were attributed to type
2 Sabin derived strains. Among the 3 endemic countries, Nigeria
and Afghanistan made substantive progress in controlling WPV1
disease with year-over-year reductions of 58% and 68%, respec-
tively, and further localization of areas experiencing endemic cases.
In contrast, Pakistan recorded 75 new cases, an increase of 34%
over 2012 due to outbreaks in areas affected by insecurity and
poor access to unvaccinated children. New WPV1 outbreaks in the
Horn of Africa (203 cases) and Syria (17 cases) were attributed to
export of WPV1 viruses from Nigeria and Pakistan, respectively,
and 4 cases of paralysis occurred in Cameroon, caused by a WPV1
strain that had been circulating undetected for an estimated 2-3
years.WPV1viruses related to the Syrianoutbreakweredetected in
environmental surveillance samples beginning in May, 2013 with-
out evidence of paralytic disease in this highly vaccinated country.
In response, the Israeli Ministry of Health has re-introduced OPV
into the national immunization schedule.
Insecurity, threats to polio vaccination teams, and gaps in sup-
plemental immunization activity (SIA) campaign quality are now
major obstacles to eradication which are being addressed by the
GPEI in multiple ways including engagement of government and
religious leaders and other relevant third parties, and introduction
of methods to assess and improve SIA coverage. Ongoing recovery
of cVDPV viruses from children with acute ﬂaccid paralysis (AFP)
and from environmental surveillance specimens in under immu-
nized areas will mean that cessation of all OPV immunization will
need to cease in a globally coordinated manner. The 2013-2018
GPEI Strategic Plan calls for complete control of all wild poliovirus
transmission the end of 2014, introduction of one or more IPV
doses for routine immunization by Q3 2015 for risk mitigation, and
replacement of all trivalent OPV with bivalent type 1 and 3 OPV
in Q2 2016. With global certiﬁcation of eradication by the end of
2018, all OPV vaccines will be discontinued and replaced by IPV.
New tools to assist in achieving and maintaining eradication
areunderdevelopment includingnew, affordable IPV formulations,
genetically stable OPV vaccines derived from current Sabin strains,
